These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 27220271

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains.
    Vainshtein I, Sun B, Roskos LK, Liang M.
    J Immunol Methods; 2020 Feb; 477():112688. PubMed ID: 31676342
    [Abstract] [Full Text] [Related]

  • 3. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
    Coddens A, Snoeck V, Bontinck L, Buyse MA, Pine SO.
    J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys.
    Wang B, Liang M, Yao Z, Vainshtein I, Lee R, Schneider A, Zusmanovich M, Jin F, O'Connor K, Donato-Weinstein B, Iciek L, Lavallee T, Roskos L.
    J Pharm Sci; 2013 Jan; 102(1):250-61. PubMed ID: 23090886
    [Abstract] [Full Text] [Related]

  • 6. Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study.
    Nishimura K, Shibata H, Aoyama M, Hosogi J, Kadotsuji K, Minoura K, Mori T, Nakamura T, Nishimiya K, Nomura T, Saito T, Soma M, Wakabayashi H, Sakamoto N, Niimi S, Katori N, Saito Y, Ishii-Watabe A.
    Bioanalysis; 2019 Mar; 11(6):509-524. PubMed ID: 30945932
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
    Kreitman RJ, Pastan I.
    Clin Cancer Res; 2011 Oct 15; 17(20):6398-405. PubMed ID: 22003067
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Development and validation of a cell based assay for the detection of neutralizing antibodies against recombinant insulins.
    Chatterjee S, Vashishta L, Waichale VS, Nayak VG, Melarkode R, Donnelly CM, Vallano PT, Chirmule N, Sengupta N.
    J Immunol Methods; 2018 Jan 15; 452():53-62. PubMed ID: 28935478
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Identification and elimination of target-related matrix interference in a neutralizing anti-drug antibody assay.
    Schwickart M, Mehrzai F, Pearson J, Shaghasi N, Chavez C, Schneider A, Wu S, Roskos L, Liang M.
    J Immunol Methods; 2014 Jan 31; 403(1-2):52-61. PubMed ID: 24287421
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A biotin-drug extraction and acid dissociation (BEAD) procedure to eliminate matrix and drug interference in a protein complex anti-drug antibody (ADA) isotype specific assay.
    Niu H, Klem T, Yang J, Qiu Y, Pan L.
    J Immunol Methods; 2017 Jul 31; 446():30-36. PubMed ID: 28389174
    [Abstract] [Full Text] [Related]

  • 17. Comparison of cell-based and non-cell-based assay platforms for the detection of clinically relevant anti-drug neutralizing antibodies for immunogenicity assessment of therapeutic proteins.
    Hu J, Wala I, Han H, Nagatani J, Barger T, Civoli F, Kaliyaperumal A, Zhuang Y, Gupta S.
    J Immunol Methods; 2015 Apr 31; 419():1-8. PubMed ID: 25795420
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Detection of Memory B Activity Against a Therapeutic Protein in Treatment-Naïve Subjects.
    Liao K, Derbyshire S, Wang KF, Caucci C, Tang S, Holland C, Loercher A, Gunn GR.
    AAPS J; 2018 Mar 16; 20(3):51. PubMed ID: 29549534
    [Abstract] [Full Text] [Related]

  • 20. Moxetumomab pasudotox for the treatment of hairy cell leukemia.
    Janus A, Robak T.
    Expert Opin Biol Ther; 2019 Jun 16; 19(6):501-508. PubMed ID: 31045462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.